Form 4: AN2 Therapeutics Director Acquires Shares in Lieu of Cash Compensation

Patricia A. Martin, a director at AN2 Therapeutics, acquired 3,166 shares of common stock as compensation in lieu of cash.

Summary

• Patricia A. Martin, a director of AN2 Therapeutics, acquired 3,166 shares of common stock on December 19, 2024.
• These shares were issued as compensation in place of cash under the company's non-employee director compensation policy.
• The shares were acquired at a price of $0 and vest immediately.

Sentiment

Score: 7

Explanation: The transaction is a routine part of director compensation and is generally viewed positively as it aligns director interests with shareholders. There is no negative information in the document.

Positives

• The acquisition of shares by a director demonstrates alignment of interests with shareholders.
• The use of shares for compensation can conserve cash resources for the company.

Industry Context

This type of transaction is common in the biotech industry, where stock-based compensation is often used to attract and retain talent, especially for non-employee directors.

Comparison to Industry Standards

• Many biotech companies use stock-based compensation for directors, aligning their interests with shareholders.
• The immediate vesting of shares is a common practice to incentivize directors.
• Comparable companies often use a mix of cash and stock for director compensation.

Stakeholder Impact

• Shareholders may view this positively as it aligns director interests with the company's performance.
• The use of stock for compensation can help conserve cash for the company.

Key Dates

Keywords

AN2 Therapeutics, Director, Share Acquisition, Compensation, Stock, ANTX, Patricia A. Martin